Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates

Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National Institutes of Health for siRNA NASH Candidates
Share Article
FARMINGTON, Conn. (PRWEB)
June 04, 2021
Mitotherapeutix LLC (MITO), a pre-clinical stage company focused on siRNA drug discovery and development based on suppression of the mitochondrial regulator MCJ (DnaJC15), today announced that it has been awarded a multi-year $2.2 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health. MITO will deploy the funds to continue IND enabling activities for siRNA candidates intended to be a novel treatment for Nonalcoholic Steatohepatitis (NASH).
“NASH remains a significant unmet medical need affecting up to 5% of all adults in the United States, according to the Liver Foundation,” said Jack Talley, Chief Executive Officer, MITO. “Our novel GalNAc conjugated-siRNA candidates are being advanced towards IND filing in late 2022. The SBIR grant will provide non-dilutive funding for rodent and monkey toxicity studies as well as pharmacodynamic studies in monkeys that are key to successful IND filing.

Related Keywords

United States ,Americans ,Jack Talley ,Oliver Foundation ,National Institute Of Diabetes ,Small Business Innovation Research ,National Institutes Of Health ,National Institutes ,Nonalcoholic Steatohepatitis ,Chief Executive Officer ,Nonalcoholic Fatty Liver Disease ,National Institute ,Kidney Diseases ,Press Release ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கர்கள் ,பலா டேலி ,கல்லீரல் அடித்தளம் ,தேசிய நிறுவனம் ஆஃப் நீரிழிவு நோய் ,சிறிய வணிக கண்டுபிடிப்பு ஆராய்ச்சி ,தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ,தேசிய நிறுவனங்கள் ,தலைமை நிர்வாகி அதிகாரி ,அல்லாத மது கொழுப்பு கல்லீரல் நோய் ,தேசிய நிறுவனம் ,கிட்நீ நோய்கள் ,ப்ரெஸ் வெளியீடு ,